<DOC>
	<DOCNO>NCT00593606</DOCNO>
	<brief_summary>This Phase 3b , open-label , multicenter trial ass safety tolerability switch ropinirole therapy rotigotine transdermal system effect symptom subject idiopathic Parkinson 's disease</brief_summary>
	<brief_title>Safety Tolerability Trial Switching From Ropinirole Rotigotine</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject inform give ample time opportunity think his/her participation trial give his/her write informed consent . Subject willing able comply trial requirement . Subject male female , aged≥ 18 year . Subject Korean . Subjects idiopathic Parkinson 's disease ( Hoehn Yahr Stage IIV ) define cardinal sign , bradykinesia , least 1 follow : rest tremor , rigidity , impairment postural reflex . Subject satisfactorily control total daily dose ropinirole 3mg 12mg , inclusive . If subject receive levodopa , either shortacting sustainedrelease ( combination benserazide carbidopa ) , total daily dose must stable 28 day prior Baseline Visit must remain stable Treatment Period . If subject receive anticholinergic agent ( eg , benztropine , trihexyphenidyl , parsitan , procyclidine , biperiden ) , monoamine oxidase B ( MAOB ) inhibitor ( eg , selegiline ) , COMT inhibitor ( eg , entacapone ) , Nmethyldaspartate ( NMDA ) antagonist ( eg , amantadine ) , he/she must stable dose least 28 day prior Baseline Visit must maintain dose Treatment Period Subjects permit enroll trial follow criterion meet : Subject previously participate trial rotigotine . Subject participate another trial investigational drug within 28 day prior Baseline Visit currently participate another trial investigational drug . Subject atypical Parkinsonian syndrome ( ) , include druginduced Parkinsonian syndrome ( ) . Subject dementia , active psychosis , hallucination ( due antiparkinsonian medication ) . Subject receive therapy 1 follow drug either concurrently within 28 day prior Baseline Visit : alphamethyl dopa , metoclopramide , reserpine , neuroleptic ( except specific atypical neuroleptic : olanzapine , ziprasidone , aripiprazole , clozapine , quetiapine ) , monoamine oxidase A ( MAOA ) inhibitor , methylphenidate , amphetamine . Subject currently receive central nervous system ( CNS ) active therapy ( eg , sedative , hypnotic , antidepressant , anxiolytic ) , unless dose stable least 28 day prior Baseline Visit likely remain stable duration trial . Subject history seizure stroke within 1 year , Transient Ischemic Attack ( TIA ) within 12 month prior enrollment , history myocardial infarction within last 6 month prior enrollment . Presence clinically relevant hepatic dysfunction . Presence clinically relevant renal dysfunction . Evidence clinically relevant cardiovascular disorder . Subject QTcB interval ≥ 500ms Pretreatment Baseline ( repeat measurement within 1 hour ) . Subject history symptomatic ( asymptomatic ) orthostatic hypotension 6 month prior Baseline . Subject history significant skin hypersensitivity adhesive transdermals recent unresolved contact dermatitis . Subject malignant neoplastic disease require therapy within 12 month prior enrollment . Subject history chronic alcohol drug abuse within last 6 month . Subject take herbal medicine therapy within last 2 week prior Baseline Visit . Subject clinically significant laboratory result , judgment investigator , would make subject unsuitable entry trial . Subject pregnant nursing , childbearing potential ( ) surgically sterile ( ii ) use adequate birth control method ( include least 1 barrier method ) , ( iii ) sexually abstinent ( iv ) least 2 year postmenopausal . Subject evidence impulse control disorder accord Jay Modified Minnesota Impulsive Disorders Interview ( mMIDI ) Pretreatment ( Visit 1 ) . Subject clinically significant medical psychiatric condition would , judgment investigator , interfere subject 's ability participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>NEUPRO</keyword>
	<keyword>Switching trial ropinirole rotigotine ,</keyword>
	<keyword>safety tolerability</keyword>
	<keyword>Parkinson disease</keyword>
</DOC>